Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$124.34
-9.9%
$131.13
$74.75
$142.00
$54.66B1.22.41 million shs8.58 million shs
Insulet Co. stock logo
PODD
Insulet
$166.19
+1.2%
$171.51
$125.82
$335.91
$11.50B0.98670,432 shs636,152 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
-9.91%-4.87%-10.85%+1.95%-0.47%
Insulet Co. stock logo
PODD
Insulet
+1.23%-0.04%-1.77%-14.97%-47.52%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
DexCom, Inc. stock logo
DXCM
DexCom
4.9558 of 5 stars
3.55.00.04.72.62.53.1
Insulet Co. stock logo
PODD
Insulet
4.882 of 5 stars
3.45.00.04.92.40.83.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DexCom, Inc. stock logo
DXCM
DexCom
2.93
Moderate Buy$141.6713.93% Upside
Insulet Co. stock logo
PODD
Insulet
2.80
Moderate Buy$243.2146.35% Upside

Current Analyst Ratings

Latest PODD and DXCM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/26/2024
DexCom, Inc. stock logo
DXCM
DexCom
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$151.00 ➝ $160.00
4/26/2024
DexCom, Inc. stock logo
DXCM
DexCom
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$144.00 ➝ $145.00
4/10/2024
DexCom, Inc. stock logo
DXCM
DexCom
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$153.00 ➝ $163.00
4/3/2024
DexCom, Inc. stock logo
DXCM
DexCom
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$148.00 ➝ $161.00
3/12/2024
DexCom, Inc. stock logo
DXCM
DexCom
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$165.00
2/26/2024
Insulet Co. stock logo
PODD
Insulet
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$214.00 ➝ $213.00
2/23/2024
Insulet Co. stock logo
PODD
Insulet
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$250.00 ➝ $230.00
2/23/2024
Insulet Co. stock logo
PODD
Insulet
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$190.00 ➝ $225.00
2/5/2024
Insulet Co. stock logo
PODD
Insulet
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$163.00 ➝ $208.00
(Data available from 4/27/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DexCom, Inc. stock logo
DXCM
DexCom
$3.62B13.59$1.86 per share66.70$5.35 per share23.24
Insulet Co. stock logo
PODD
Insulet
$1.70B6.86$3.84 per share43.26$10.49 per share15.84

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DexCom, Inc. stock logo
DXCM
DexCom
$541.50M$1.5580.2255.762.3716.82%31.38%10.26%7/25/2024 (Estimated)
Insulet Co. stock logo
PODD
Insulet
$206.30M$2.9157.1142.942.9612.16%32.19%7.93%5/9/2024 (Confirmed)

Latest PODD and DXCM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Insulet Co. stock logo
PODD
Insulet
$0.39N/A-$0.39N/AN/AN/A  
4/25/2024Q1 2024
DexCom, Inc. stock logo
DXCM
DexCom
$0.27$0.32+$0.05$0.28$911.20 million$921.00 million    
2/22/2024Q4 2023
Insulet Co. stock logo
PODD
Insulet
$0.67$1.40+$0.73$1.36$461.26 million$509.80 million    
2/8/2024Q4 2023
DexCom, Inc. stock logo
DXCM
DexCom
$0.43$0.50+$0.07$0.38$1.02 billion$1.03 billion      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Insulet Co. stock logo
PODD
Insulet
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DexCom, Inc. stock logo
DXCM
DexCom
1.18
2.84
2.48
Insulet Co. stock logo
PODD
Insulet
1.86
3.51
2.62

Ownership

Institutional Ownership

CompanyInstitutional Ownership
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Insulet Co. stock logo
PODD
Insulet
N/A

Insider Ownership

CompanyInsider Ownership
DexCom, Inc. stock logo
DXCM
DexCom
0.41%
Insulet Co. stock logo
PODD
Insulet
0.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
DexCom, Inc. stock logo
DXCM
DexCom
9,600396.03 million394.40 millionOptionable
Insulet Co. stock logo
PODD
Insulet
3,00070.02 million69.39 millionOptionable

PODD and DXCM Headlines

SourceHeadline
Insulet (PODD) Outperforms Broader Market: What You Need to KnowInsulet (PODD) Outperforms Broader Market: What You Need to Know
zacks.com - April 26 at 7:16 PM
Stevens Capital Management LP Has $324,000 Stake in Insulet Co. (NASDAQ:PODD)Stevens Capital Management LP Has $324,000 Stake in Insulet Co. (NASDAQ:PODD)
marketbeat.com - April 26 at 6:42 PM
Texas Instruments stock pops on Q2 revenue outlookTexas Instruments stock pops on Q2 revenue outlook
finance.yahoo.com - April 26 at 5:03 PM
Insulet (PODD) Awaits Q1 Earnings Release: Heres What to ExpectInsulet (PODD) Awaits Q1 Earnings Release: Here's What to Expect
zacks.com - April 24 at 9:46 AM
Insulet Co. (NASDAQ:PODD) Shares Purchased by Jennison Associates LLCInsulet Co. (NASDAQ:PODD) Shares Purchased by Jennison Associates LLC
marketbeat.com - April 24 at 7:26 AM
Insulet Co. (NASDAQ:PODD) Stock Position Trimmed by abrdn plcInsulet Co. (NASDAQ:PODD) Stock Position Trimmed by abrdn plc
marketbeat.com - April 21 at 9:31 AM
Federated Hermes Inc. Boosts Stake in Insulet Co. (NASDAQ:PODD)Federated Hermes Inc. Boosts Stake in Insulet Co. (NASDAQ:PODD)
marketbeat.com - April 20 at 7:17 AM
5 Large-Cap Medical Stocks to Buy Ahead of Q1 Earnings5 Large-Cap Medical Stocks to Buy Ahead of Q1 Earnings
zacks.com - April 19 at 8:50 AM
Why Investors Need to Take Advantage of These 2 Medical Stocks NowWhy Investors Need to Take Advantage of These 2 Medical Stocks Now
zacks.com - April 17 at 9:51 AM
Earnings growth outpaced the impressive 16% CAGR delivered to Insulet (NASDAQ:PODD) shareholders over the last five yearsEarnings growth outpaced the impressive 16% CAGR delivered to Insulet (NASDAQ:PODD) shareholders over the last five years
finance.yahoo.com - April 15 at 11:41 AM
7 Stable Stocks for 50% Returns by Early 20257 Stable Stocks for 50% Returns by Early 2025
investorplace.com - April 15 at 9:45 AM
Aquila Investment Management LLC Makes New $1.30 Million Investment in Insulet Co. (NASDAQ:PODD)Aquila Investment Management LLC Makes New $1.30 Million Investment in Insulet Co. (NASDAQ:PODD)
marketbeat.com - April 14 at 9:39 AM
Lecap Asset Management Ltd. Makes New $1.51 Million Investment in Insulet Co. (NASDAQ:PODD)Lecap Asset Management Ltd. Makes New $1.51 Million Investment in Insulet Co. (NASDAQ:PODD)
marketbeat.com - April 13 at 8:08 PM
Shaker Investments LLC OH Raises Stock Position in Insulet Co. (NASDAQ:PODD)Shaker Investments LLC OH Raises Stock Position in Insulet Co. (NASDAQ:PODD)
marketbeat.com - April 12 at 11:23 PM
Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report?Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report?
zacks.com - April 12 at 1:16 PM
Insulet (PODD) Stock Moves -0.34%: What You Should KnowInsulet (PODD) Stock Moves -0.34%: What You Should Know
finance.yahoo.com - April 10 at 11:34 PM
Baillie Gifford & Co. Invests $263.14 Million in Insulet Co. (NASDAQ:PODD)Baillie Gifford & Co. Invests $263.14 Million in Insulet Co. (NASDAQ:PODD)
marketbeat.com - April 10 at 8:24 AM
Insulet (NASDAQ:PODD) Trading Up 4.8%Insulet (NASDAQ:PODD) Trading Up 4.8%
marketbeat.com - April 9 at 12:12 PM
Asset Management One Co. Ltd. Purchases 9,240 Shares of Insulet Co. (NASDAQ:PODD)Asset Management One Co. Ltd. Purchases 9,240 Shares of Insulet Co. (NASDAQ:PODD)
marketbeat.com - April 9 at 5:17 AM
Advisors Preferred LLC Purchases Shares of 13,403 Insulet Co. (NASDAQ:PODD)Advisors Preferred LLC Purchases Shares of 13,403 Insulet Co. (NASDAQ:PODD)
marketbeat.com - April 5 at 5:35 PM
Top buy-rated stocks and sell-rated stocks within Health Care - CitiTop buy-rated stocks and sell-rated stocks within Health Care - Citi
msn.com - April 4 at 11:33 AM
Insulet applauds as UK begins artificial pancreas rolloutInsulet applauds as UK begins artificial pancreas rollout
drugdeliverybusiness.com - April 4 at 11:33 AM
Nadav Eiron Joins Crusoe as Senior Vice President of Cloud EngineeringNadav Eiron Joins Crusoe as Senior Vice President of Cloud Engineering
businesswire.com - April 3 at 6:00 AM
Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
businesswire.com - April 3 at 6:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

DexCom logo

DexCom

NASDAQ:DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Insulet logo

Insulet

NASDAQ:PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.